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showed that platelets contribute to acute liver damage by pro-
moting the intrahepatic accumulation of virus-speciﬁc CD8 T
cells and, secondarily, virus-non-speciﬁc inﬂammatory cells. Built
on these observations, a recent preclinical study took advantage
of a previously established hepatitis B virus (HBV) transgenic
mouse model of immune-mediated chronic hepatitis that pro-
gresses to hepatocellular carcinoma (HCC), to demonstrate that
clinically achievable doses of the anti-platelet drugs aspirin and
clopidogrel – administered continuously after the onset of liver
disease – can prevent hepatocarcinogenesis and greatly improve
overall survival. These outcomes were preceded by and associ-
ated with reduced hepatic accumulation of virus-speciﬁc CD8 T
cells and virus-non-speciﬁc inﬂammatory cells, reduced hepato-
cellular injury and hepatocellular proliferation, and reduced
severity of liver ﬁbrosis. The observation that anti-platelet ther-
apy inhibits HCC development identiﬁes platelets as key players
in the pathogenesis of HBV-associated liver cancer and supports
the notion that a sustained immune-mediated necroinﬂammato-
ry liver disease is sufﬁcient to trigger HCC. The results abovemen-
tioned and their clinical implications are discussed in this report.
 2013 European Association for the Study of the Liver. Published
by Elsevier B.V.
HCC is the ﬁfth most frequently diagnosed cancer worldwide and
the third leading cause of cancer-related death [1]. Poor progno-
sis of HCC-bearing patients is linked to the relative resistance of
this cancer to radio- or chemo-therapy and the limited success of
surgical (tumor resection or liver transplantation), percutaneous
(ethanol injection or radiofrequency thermal ablation) and tran-
sarterial (embolization or chemoembolization) interventions [2].
Open access under CC BY-NC-ND license.HBV is a non-cytopathic DNA virus whose host range is lim-
ited to humans and chimpanzees and whose tropism is limited
to the parenchymal cell of the liver, i.e., the hepatocyte [3].
HBV can cause persistent infection, ﬁbrosis, and cirrhosis of the
liver and it is globally responsible for more than 50% of HCC casesJournal of Hepatology 20
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procarcinogenic genes due to HBV DNA integration and/or the
expression of HBV-derived procarcinogenic polypeptides), host
factors seem to play a predominant role in this process [3]. The
interval between viral infection and HCC is typically several dec-
ades, indicating that HBV is not acutely oncogenic. Further,
almost all HCC cases occur after many years of immune-mediated
chronic hepatitis [3]. Chronic hepatitis B (CHB) is characterized
by a functionally inefﬁcient virus-speciﬁc CD8 T-cell response
that fails to eliminate HBV from the liver but maintains continu-
ous cycles of low-level hepatocellular injury, promoting hepato-
cellular proliferation and exposing proliferating hepatocytes to
inﬂammatory mutagens [3]. Over time, the persistence of necro-
sis, regeneration, and inﬂammation coupled with compromised
repair functions is thought to trigger random genetic and chro-
mosomal alterations ultimately leading to HCC development [3].
Prevention of HBV infection by universal infant vaccination is
starting to produce a positive impact on HCC incidence [4]. Termi-
nation of chronicHBV infection by available antiviral therapies has
also been associated with reduced occurrence of HCC [5,6]. Unfor-
tunately, the majority of CHB patients do not respond to these
therapieswith sustained virus elimination (because of limited efﬁ-
cacy, dose-limiting side effects, high costs and the emergence of
drug-resistant mutants [7]). As such, a huge burden of cancer risk
remains in store for more than 350 million people chronically
infected with HBV [4]. Based on these considerations, it becomes
apparent that new drugs reducing the risk of HCC in these individ-
ualswillmeet a pressing need. Relevant to this, a recent preclinical
study of ours suggested that aspirin and clopidogrel – two anti-
platelet drugswidely used in humans for the prevention of arterial
thrombosis [8] – inhibit the development of HCCs emerging from a
context of immune-mediated chronic liver injury [9]. The research
that led to this preclinical study, the mechanisms whereby anti-
platelet drugsmay exert anti-HCC potential and the clinical impli-
cations of these ﬁndings are discussed below.
Asmentioned earlier, virus-speciﬁc CD8 T cells are key triggers
of hepatic immunopathology during HBV infection [3]. Previous
work from our laboratory has also outlined a role for platelets in
this process. Indeed, we used two mouse models of self-limited
acute viral hepatitis in which hepatocellular damage is resolved
in a few days (HBV transgenic mice transferred with HBV-speciﬁc
CD8 T cells or wild type mice infected with hepatotropic adenovi-
rus) to show that platelets are present at sites of organ damage;13 vol. 59 j 1135–1138
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their depletion reduces the number of virus-speciﬁc CD8 T
cells (and the number of virus-non-speciﬁc inﬂammatory cells
that CD8 T cells secondarily recruit into the liver) ameliorating dis-
ease severity; and this positive outcome is reversed by reconstitut-
ing thrombocytopenic animals with normal but not dysfunctional
platelets [10]. In an ongoing effort to explain mechanistically why
platelets are required to support the intrahepatic accumulation of
virus-speciﬁc CD8 T cells, we found that this function is inﬂuenced
by two speciﬁc inhibitors of platelet activation pathways, aspirin
that blocks thromboxane (TX) A2 production and clopidogrel that
blocks the P2Y12 ADP receptor [8]. Treating adenovirus-infected
mice with aspirin, clopidogrel, or a combination of the two atten-
uates the acute accumulation of virus-speciﬁc CD8 T cells in the
liver and the associated organ damage [11].
Considering that oral administration of aspirin and clopido-
grel can be used for long-term treatment of patients at risk of
thrombosis, we then took advantage of a previously established
mouse model of immune-mediated CHB [12] to evaluate if and
how the sustained inhibition of platelet activation may impact
the severity of chronic liver injury and its complications. Treating
these mice with clinically relevant doses of aspirin and clopido-
grel – beginning after the induction of hepatitis and continuing
indeﬁnitely – limited the intrahepatic accumulation of both
virus-speciﬁc CD8 T cells and virus-non-speciﬁc inﬂammatory
cells and the consequent hepatocellular injury, reduced compen-
satory hepatocellular proliferation, diminished the severity of
liver ﬁbrosis, prevented HCC development and, more impor-
tantly, improved overall survival [9]. These results indicate that
platelets inﬂuence the chronic stages of a pathogenic mechanism
triggered by virus-speciﬁc CD8 T cells, and strongly imply that
immune-mediated inﬂammatory reactions are the predominant
cause of HCC transformation during chronic HBV infection.
The ability of aspirin/clopidogrel to counteract the intrahe-
patic accumulation of virus-speciﬁc CD8 T cells may be sufﬁcient
to explain the outcome of our study. In contrast, long-term anti-
platelet treatment had no effect on the phenotype of HBV-speciﬁc
CD8 T cells, which remained similar to that of chronically infected
patients [13] with retention of target cell killing activity but low
expression of IFN-c capable of inhibiting HBV replication [14]. If
a functional link exists between platelets and CD8 T cells, it is still
undeﬁned. We have proposed that activation-dependent expres-
sion of platelet CD40 ligand may contribute to the expansion
phase of virus-speciﬁc CD8 T cells resulting in their accumulation
at sites of infection [15]. In fact, evidence obtained by others indi-
cates that platelet CD40 ligand modulates multiple aspects of
adaptive immunity [16]. Whether the functional connection
between platelets and T cells depends on direct intercellular con-
tacts remains to be fully demonstrated; recent experiments utiliz-
ing intravital microscopy, however, are telling us that platelet-T
cell interactions do occur within the hepatic microcirculation.
An alternative explanation for the pathogenic role of platelets
in aggravating viral hepatitis has been based on ﬁndings in mice
acutely infected with lymphocytic choriomeningitis virus (LCMV)
[17], a virus that – unlike HBV – in the liver infects primarily res-
ident macrophages. In this model, vasoactive serotonin released
from activated platelets appears to promote liver damage by per-
turbing the liver microcirculation, thus delaying the intrahepatic
inﬂux of CD8 T cells mediating LCMV clearance. It remains to be
ascertained whether serotonin-dependent hemodynamic distur-
bances can also inﬂuence HBV-related immunopathology in our
transgenic hepatitis model. Recently, it has been shown that1136 Journal of Hepatology 2013platelet-derived serotonin supports HCC development in mice
chronically exposed to carbon tetrachloride (CCl4) [18], a situa-
tion in which carcinogenesis is independent of adaptive immune
responses. Of note, our recent study indicated that HCC develop-
ment in mice similarly treated (i.e., chronically exposed to CCl4)
is not inﬂuenced by anti-platelet therapy [9]. Although indirectly,
this may argue against the hypothesis that the aspirin/clopido-
grel-dependent amelioration of HCC observed in mice undergo-
ing immune-mediated chronic hepatitis reﬂects the inhibition
of serotonin-dependent pathways. The lack of efﬁcacy of anti-
platelet therapy in CCl4-treated mice [9] is also an argument
against the possibility that platelet-derived angiogenic factors
thought to be involved in the development of CCl4-induced HCC
[19,20] may be targets of aspirin/clopidogrel treatment. Direct
evidence for or against a possible role of platelet-derived seroto-
nin and growth factors in immune-mediated chronic hepatitis is
yet to be obtained.
Furthermore, the observation that mice undergoing immune-
mediated CHB showed presence of small platelet aggregates only
within hepatic necroinﬂammatory foci and absence of liver
infarction [9] contradicts the possibility that anti-platelet therapy
suppresses liver disease by inhibiting the formation of vessel-
occluding clots. This is consistent with what observed in models
of acute hepatitis, where vessel-occluding clots do not develop
and warfarin-based anticoagulant therapy (preventing ﬁbrin
deposition) does not affect the capacity of virus-speciﬁc CD8+ T
cells to cause liver damage [10].
It is noteworthy that aspirin alone – at a dosage known to
markedly inhibit the release of serotonin and other small
molecules from dense granules – has no effect on the release of
a-granule content – where proteins and peptides are stored
[21]. This is relevant in relation to the potential role of platelet-
derived proteins in the functional cross-talk with lymphocytes;
for example, CD40 ligand and P-selectin translocate to the plate-
let membrane surface in association with the activation-induced
a-granule release reaction [22]. Unlike aspirin, clopidogrel has
been found by different investigators to downregulate the
expression of markers of inﬂammation, including CD40 ligand
and P-selectin, on the surface of activated platelets, an effect
through which it inhibits heterotypic platelet-leukocyte interac-
tions linking vascular injury to inﬂammation [23]. Therefore,
the beneﬁcial effect of dual anti-platelet therapy in ameliorating
the course of immune-mediated chronic hepatitis may involve
distinct pharmacologic effects of the two administered drugs. In
synergy, they may reduce platelet contribution to a complex
pathogenic mechanism in which multiple pathways modulate
intrahepatic virus-speciﬁc CD8 T-cell accumulation in the liver.
In this regard it is relevant to note that, at the low dose used,
aspirin has almost exclusively platelet-speciﬁc effects with min-
imal anti-inﬂammatory properties [8]; in keeping with this, we
found that the hepatic expression of COX-2 (a pro-inﬂammatory
enzyme that is not produced by platelets [8]) and its relative
activity were not reduced in mice treated with dual anti-platelet
therapy (unpublished observation).
Altogether, the results presented in [9] indicated that the anti-
platelet drugs aspirin and clopidogrel effectively prevent HCC and
improve survival in a relevant mouse model of CHB, supporting
the concept that platelets promote hepatic immunopathology fol-
lowing activation events that require normal production of TX-A2
and normal response to ADP. With the limitation that this study
could not assess the impact of anti-platelet therapy on HBVvol. 59 j 1135–1138
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replication and viremia, the results also reinforce the notion that
a detrimental CD8 T-cell response is both necessary and sufﬁcient
to induce liver cancer during chronic viral hepatitis and they sug-
gest that drugs targeting platelet function may be a therapeutic
option in patients with chronic HBV infection.
Key Points
• Platelets promote the intrahepatic accumulation of
virus-specific CD8 T cells in mouse models of acute
HBV infection
• Virus-specific CD8 T cells induce liver injury by killing
HBV-replicating hepatocytes and by secondarily 
recruiting pathogenic virus-non-specific inflammatory
cells
• The anti-platelet drugs aspirin and clopidogrel inhibit
the intrahepatic accumulation of virus-specific CD8 T
cells and virus-non-specific inflammatory cells
• Sustained administration of aspirin and clopidogrel
in mouse models of chronic HBV infection reduces
the severity of persistent liver injury and prevent HCC
development
• Anti-platelet therapy may represent a novel therapeutic
option in patients with chronic HBV infection
A concern about such a treatment could be increasing bleed-
ing risk in individuals with compromised coagulation associated
with impaired liver function. However, as pointed out in a recent
review [24], excessive bleeding that is prevalent in the advanced
stage of liver cirrhosis may be a lesser risk than thrombosis in
some subgroups of patients with CHB. The presence of a pro-
coagulant imbalance in these patients suggests that anti-platelet
therapy might be beneﬁcial at preventing both thrombosis and
HCC development. Notably, a large observational study recently
indicated that the use of aspirin reduces the risk of HCC in
patients suffering from chronic liver disease of unspeciﬁed etiol-
ogies [25]. Although caution should be taken before evaluating
observational studies that lack pretreatment patient stratiﬁcation
and randomized control group inclusion, these results coupled
with our preclinical observations strengthen the rationale of
designing future clinical trials aimed at speciﬁcally evaluating
the impact of anti-platelet therapy in CHB patients. Prospective
studies in CHB patients will require careful patient selection
(for instance initially excluding patients with advanced liver dis-
ease), extended follow-up, frequent monitoring of viral parame-
ters and, possibly, the concomitant use of nucleoside inhibitors
inhibiting HBV. The design of these studies could also beneﬁt
from additional preclinical work in woodchucks experimentally
infected with WHV. WHV is a HBV-related hepadnavirus induc-
ing transient or persistent immune-mediated liver diseases that
resemble those observed in HBV-infected humans [26]. There,
the evaluation of the impact that anti-platelet therapy will have
on bleeding risk, WHV viremia and overall liver disease severity
may provide useful information, particularly on the possibility
that the anti-platelet therapy-dependent inhibition of intrahe-
patic T-cell accumulation may result on viral reactivation.Journal of Hepatology 2013Financial support
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